Farshidfar and colleagues identified that acral melanomas have a lower overall immune cell infiltrate as compared to traditional cutaneous melanoma, but of these infiltrates, PD-1, LAG-3, CTLA-4, VISTA, TIGIT, and ADORA2 were highly expressed, introducing new possible therapeutic targets [130]. Here, CTLA4 is linked to acral lentiginous melanoma.